// App-Quantinova.ai

176 : Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through three years: long-term results of two randomised double-blind placebo-controlled phase III studies

Researchers

Presenter

  • Helena Marzo-Ortega

Principal Investigators

  • Tore K Kvien

  • Atul A Deodhar

  • Laure Gossec

  • Philip G Conaghan

  • Vibeke Strand

  • Mikkel stergaard

  • Nicole Williams

  • Brian Porter

  • Kunal Gandi

  • Steffen Jugl

Medical Centers

  • NIHR Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UNITED KINGDOM

  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

  • Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

  • Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR

  • Rheumatology, UPMC University Paris 06 and Pitie-Salpétriere Hospital, Paris, FRANCE

  • Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, CA

  • Copenhagen Center for Arthritis Research (COPECARE), Rigshospitalet, Glostrup, DENMARK

  • Patient Centered Outcomes Assessment, RTI‐Health Solutions, Raleigh‐Durham, NC

  • Immunology and Dermatology Franchise, Novartis Pharma AG, East Hanover, NJ

  • Immunology and Dermatology Franchise, Novartis Pharma AG, East Hanover, NJ

  • Immunology & Dermatology Franchise, Novartis Pharma AG, Basel, SWITZERLAND

Locations

  • United Kingdom

  • Norway

  • United States

  • France

  • Denmark

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Ankylosing spondylitis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT01863732

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved